ZA200805599B - RNAI-mediated inhibition of Rho kinase for treatment of ocular hypertension/glaucoma - Google Patents
RNAI-mediated inhibition of Rho kinase for treatment of ocular hypertension/glaucomaInfo
- Publication number
- ZA200805599B ZA200805599B ZA200805599A ZA200805599A ZA200805599B ZA 200805599 B ZA200805599 B ZA 200805599B ZA 200805599 A ZA200805599 A ZA 200805599A ZA 200805599 A ZA200805599 A ZA 200805599A ZA 200805599 B ZA200805599 B ZA 200805599B
- Authority
- ZA
- South Africa
- Prior art keywords
- rnai
- glaucoma
- treatment
- ocular hypertension
- mediated inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75409405P | 2005-12-27 | 2005-12-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200805599B true ZA200805599B (en) | 2009-11-25 |
Family
ID=38218805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200805599A ZA200805599B (en) | 2005-12-27 | 2006-12-19 | RNAI-mediated inhibition of Rho kinase for treatment of ocular hypertension/glaucoma |
Country Status (14)
Country | Link |
---|---|
US (4) | US20070149473A1 (xx) |
EP (2) | EP1989305A2 (xx) |
JP (2) | JP2009532325A (xx) |
KR (1) | KR20080079264A (xx) |
CN (1) | CN101326285A (xx) |
AR (1) | AR057252A1 (xx) |
AU (1) | AU2006330606A1 (xx) |
BR (1) | BRPI0621264A2 (xx) |
CA (2) | CA2821393A1 (xx) |
RU (2) | RU2432165C2 (xx) |
TW (1) | TW200731979A (xx) |
UY (1) | UY30060A1 (xx) |
WO (1) | WO2007076367A2 (xx) |
ZA (1) | ZA200805599B (xx) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7470787B2 (en) * | 2005-07-11 | 2008-12-30 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds |
US20070135499A1 (en) * | 2005-07-11 | 2007-06-14 | Aerie Pharmaceuticals, Inc. | Hydrazide compounds |
WO2008036540A2 (en) | 2006-09-20 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
RU2010117178A (ru) * | 2007-10-01 | 2011-11-10 | Алькон Рисерч, Лтд. (Us) | Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний |
US7973019B1 (en) | 2007-10-03 | 2011-07-05 | Alcon Research, Ltd. | Transferrin/transferrin receptor-mediated siRNA delivery |
TW200930405A (en) * | 2007-11-15 | 2009-07-16 | Alcon Res Ltd | Low density lipoprotein receptor-mediated siRNA delivery |
AR069704A1 (es) | 2007-12-18 | 2010-02-10 | Alcon Res Ltd | Sistema de administracion de rnai de interferencia y usos del mismo |
US8455514B2 (en) | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
US8450344B2 (en) * | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
CN101643729B (zh) * | 2008-08-07 | 2011-12-28 | 复旦大学 | 核酸分子nrn1sr22及其在制备抗癌药物中的应用 |
JP2012525386A (ja) | 2009-05-01 | 2012-10-22 | アエリエ・ファーマシューティカルズ・インコーポレーテッド | 疾患の治療のための二重機構阻害剤 |
WO2011021221A2 (en) | 2009-08-17 | 2011-02-24 | Reliance Life Sciences Pvt. Ltd. | Compositions for spinal cord injury |
DK3124610T3 (da) * | 2010-10-28 | 2019-06-11 | Benitec Biopharma Ltd | Hbv-behandling |
CN102343091A (zh) * | 2011-03-01 | 2012-02-08 | 中国科学技术大学 | 一种基于ezrin磷酸化的物质及其应用 |
WO2012161677A1 (en) | 2011-05-20 | 2012-11-29 | Alcon Research, Ltd. | TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY |
WO2013103467A1 (en) | 2012-01-06 | 2013-07-11 | Alcon Research, Ltd. | Interfering rna delivery system and uses thereof |
CN109528721B (zh) | 2013-03-15 | 2021-10-01 | 爱瑞制药公司 | 联合治疗 |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
US10550087B2 (en) | 2015-11-17 | 2020-02-04 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
KR102568082B1 (ko) | 2016-08-31 | 2023-08-17 | 에어리 파마슈티컬즈, 인코포레이티드 | 안과용 조성물 |
CN108531453B (zh) * | 2017-03-01 | 2020-12-18 | 中国科学院动物研究所 | 一种将非神经元细胞转化为神经元细胞的方法 |
AU2018243687C1 (en) | 2017-03-31 | 2020-12-24 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US11427563B2 (en) | 2018-09-14 | 2022-08-30 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
AU2022357497A1 (en) * | 2021-09-30 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Treatment of glaucoma with rho guanine nucleotide exchange factor 12 (arhgef12) inhibitors |
WO2023239756A1 (en) | 2022-06-07 | 2023-12-14 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU230458B1 (hu) * | 2000-12-01 | 2016-07-28 | Europäisches Laboratorium für Molekularbiologie (EMBL) | Az RNS interferenciát közvetítő kis RNS molekulák |
US20050222029A1 (en) * | 2001-01-04 | 2005-10-06 | Myriad Genetics, Incorporated | Compositions and methods for treating diseases |
US20040115641A1 (en) * | 2002-12-11 | 2004-06-17 | Isis Pharmaceuticals Inc. | Modulation of ROCK 1 expression |
JP2006507841A (ja) * | 2002-11-14 | 2006-03-09 | ダーマコン, インコーポレイテッド | 機能的siRNAおよび超機能的siRNA |
US20050019746A1 (en) * | 2003-01-23 | 2005-01-27 | Eirx Therapeutics Limited | Apoptosis-related kinase/GPCRs |
WO2004087744A2 (en) * | 2003-03-28 | 2004-10-14 | Intellectual Property Consulting Inc. | Composition and method for nerve regeneration |
EP3168304A1 (en) * | 2003-08-27 | 2017-05-17 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
WO2005063983A1 (en) * | 2003-12-29 | 2005-07-14 | Galapagos Genomics N.V. | Modulators of bone homeostasis identified in a high-throughput screen |
WO2005085469A2 (en) * | 2004-03-09 | 2005-09-15 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1) |
WO2005085466A2 (en) * | 2004-03-09 | 2005-09-15 | Bayer Healtcare Ag | Diagnostic and therapeutics for diseases associated with rho-associated protein kinase 2 (rock2) |
WO2005117938A2 (en) * | 2004-04-13 | 2005-12-15 | Regents Of The University Of Minnesota | Methods of treating ocular conditions |
-
2006
- 2006-12-15 AR ARP060105556A patent/AR057252A1/es unknown
- 2006-12-18 TW TW095147452A patent/TW200731979A/zh unknown
- 2006-12-19 EP EP06848926A patent/EP1989305A2/en not_active Ceased
- 2006-12-19 CA CA2821393A patent/CA2821393A1/en not_active Abandoned
- 2006-12-19 RU RU2008130855/15A patent/RU2432165C2/ru not_active IP Right Cessation
- 2006-12-19 US US11/641,410 patent/US20070149473A1/en not_active Abandoned
- 2006-12-19 WO PCT/US2006/062318 patent/WO2007076367A2/en active Application Filing
- 2006-12-19 CN CNA200680046457XA patent/CN101326285A/zh active Pending
- 2006-12-19 EP EP13152376.3A patent/EP2592144A1/en not_active Withdrawn
- 2006-12-19 CA CA002631840A patent/CA2631840A1/en not_active Abandoned
- 2006-12-19 ZA ZA200805599A patent/ZA200805599B/xx unknown
- 2006-12-19 AU AU2006330606A patent/AU2006330606A1/en not_active Abandoned
- 2006-12-19 KR KR1020087014716A patent/KR20080079264A/ko not_active Application Discontinuation
- 2006-12-19 JP JP2008548811A patent/JP2009532325A/ja active Pending
- 2006-12-19 BR BRPI0621264-6A patent/BRPI0621264A2/pt not_active IP Right Cessation
- 2006-12-21 UY UY30060A patent/UY30060A1/es not_active Application Discontinuation
-
2009
- 2009-07-09 US US12/500,239 patent/US20090275641A1/en not_active Abandoned
-
2010
- 2010-11-05 US US12/940,375 patent/US8168609B2/en not_active Expired - Fee Related
-
2011
- 2011-06-16 RU RU2011124528/15A patent/RU2011124528A/ru not_active Application Discontinuation
-
2012
- 2012-03-26 US US13/429,889 patent/US20120178794A1/en not_active Abandoned
- 2012-07-13 JP JP2012157529A patent/JP2012193210A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20080079264A (ko) | 2008-08-29 |
US20120178794A1 (en) | 2012-07-12 |
US20070149473A1 (en) | 2007-06-28 |
CN101326285A (zh) | 2008-12-17 |
US20090275641A1 (en) | 2009-11-05 |
WO2007076367A2 (en) | 2007-07-05 |
CA2821393A1 (en) | 2007-07-05 |
UY30060A1 (es) | 2007-04-30 |
AU2006330606A1 (en) | 2007-07-05 |
RU2008130855A (ru) | 2010-02-10 |
WO2007076367A3 (en) | 2008-04-17 |
JP2009532325A (ja) | 2009-09-10 |
JP2012193210A (ja) | 2012-10-11 |
EP2592144A1 (en) | 2013-05-15 |
US8168609B2 (en) | 2012-05-01 |
RU2432165C2 (ru) | 2011-10-27 |
TW200731979A (en) | 2007-09-01 |
CA2631840A1 (en) | 2007-07-05 |
RU2011124528A (ru) | 2012-12-27 |
EP1989305A2 (en) | 2008-11-12 |
US20110245319A1 (en) | 2011-10-06 |
AR057252A1 (es) | 2007-11-21 |
BRPI0621264A2 (pt) | 2011-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200805599B (en) | RNAI-mediated inhibition of Rho kinase for treatment of ocular hypertension/glaucoma | |
ZA200704932B (en) | Rnai inhibition of CTGF for treatment of ocular disorders | |
WO2007059257A3 (en) | N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | |
WO2008011560A3 (en) | Benzothiophene inhibitors of rho kinase | |
EP1732484A4 (en) | OPHTHALMIC IMPLANT FOR THE TREATMENT OF GLAUCOMA | |
IL186598A0 (en) | Composition and method for the treatment or prevention of glaucoma and ocular hypertension | |
EP2063882A4 (en) | TYROSINKINASE INHIBITOR FOR PREVENTING OR TREATING INFECTIONS | |
HK1140827A1 (en) | Ophthalmic lenses for prevention of myopia progression | |
EP1646614A4 (en) | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA | |
WO2008083252A3 (en) | Methods of use for cyclopamine analogs | |
HK1112718A1 (en) | Aqueous ophthalmic suspension of crystalline rebamipide | |
IL178100A0 (en) | 5-amino-4-hydroxy-7-(1h-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension | |
PL2026775T3 (pl) | Zastosowanie inhibitorów kinazy tyrozynowej Syk w leczeniu komórkowych zaburzeń proliferacyjnych | |
ZA200900553B (en) | Rnai-Mediated inhibition of gremlin for treatment of IOP-related conditions | |
WO2008036459A8 (en) | Inhibitors of rho kinase | |
IL176141A0 (en) | Crystalline forms of valacyclovir hydrochloride | |
IL207397A0 (en) | Difluorobiphenylamide derivtives for the treatment of ocular hypertension | |
PL1905452T3 (pl) | Środek do zapobiegania lub leczenia jaskry | |
IL198941A0 (en) | Isosorbide mononitrate derivatives for the treatment of ocular hypertension | |
WO2007014250A8 (en) | Abl kinase inhibition | |
EP1664011A4 (en) | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA | |
IL188787A (en) | Preparations for the treatment of diabetic eye complications | |
EP2032130A4 (en) | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF EYE HIGH PRESSURE | |
EP1771170A4 (en) | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA | |
EP1890711A4 (en) | COMPOUNDS FOR THE TREATMENT OR PREVENTION OF AMINOXIDASE-RELATED DISEASES OR DISEASES |